In the BioHarmony Drug Report Database

"Preview" Icon

Asenapine

Secuado, Sycrest (asenapine) is a small molecule pharmaceutical. Asenapine was first approved as Secuado on 2010-09-01. It is used to treat bipolar disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, 5-hydroxytryptamine receptor 1E, and 5-hydroxytryptamine receptor 1A. Saphris’s patent is valid until 2033-07-25 (FDA).

 

Trade Name

 

Sycrest
 

Common Name

 

asenapine
 

ChEMBL ID

 

CHEMBL3187365
 

Indication

 

bipolar disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
 

Drug Class

 

Tricyclic compounds

Image (chem structure or protein)

Asenapine structure rendering